Swissmedic Authorises New Therapeutic Use for Trecondi®

Swissmedic has announced an update regarding the medication Trecondi®. On October 31, 2025, the regulatory body…

Swissmedic Grants First Authorisation for SWAN-PSMA-1007®: Key Regulatory Insights

On October 31, 2025, Swissmedic announced the first authorisation of SWAN-PSMA-1007®, marking a significant regulatory milestone.…

Swissmedic Updates Position Paper on Decentralised Clinical Trials: Key Changes Explained

On October 31, 2025, Swissmedic and swissethics announced an update to their position paper on decentralised…

Swissmedic Approves Extended Therapeutic Indication for Omvoh®

Swissmedic has announced an important update regarding the therapeutic scope of Omvoh®. The newly approved indication…

Safety Alert: Recall of NaCl B. Braun Infusion Solution Batch

Swissmedic has issued an announcement regarding the immediate recall of batch number 251347651 of NaCl B.…

Swissmedic Expands Therapeutic Indication for Palforzia®

Swissmedic, Switzerland’s agency for the authorization and supervision of therapeutic products, has announced an extension of…

Swissmedic Announces Authorization of Ayvakyt®: A Clinical Update

Swissmedic, the Swiss agency for therapeutic products, has announced the first regulatory authorization for Ayvakyt®. This…

Swissmedic Grants Initial Authorization for Wainzua®: Key Regulatory Update

Swissmedic, the Swiss agency responsible for licensing and monitoring therapeutic products, has announced the initial authorization…

Tamsulosin and Its Association with Intraoperative Floppy Iris Syndrome: Swissmedic Insights

Swissmedic has issued an important notice about the risks of intraoperative floppy iris syndrome (IFIS) among…

Swissmedic Updates on Veterinary Drug Reactions: Key Insights from 2024 Reports

The latest vigilance report from Swissmedic highlights significant findings regarding adverse reactions to veterinary medicinal products…